Andrei Barasch1, Hongyan Li2, Vinagolu K Rajasekhar2, Judith Raber-Durlacher3, Joel B Epstein4, James Carroll5, Adriana Haimovitz-Friedman2. 1. Department of Medicine, Weil Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA. barasaff@cs.com. 2. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University, and University Medical Centers, location AMC, Amsterdam, The Netherlands. 4. Cedars-Sinai Health System, Los Angeles and City of Hope Cancer Center, Duarte, CA, USA. 5. Thor Photomedicine Ltd, Chesham, UK.
Abstract
BACKGROUND: Photobiomodulation (PBM) has shown efficacy in preventing and treating cancer therapy-induced mucositis and dermatitis. However, there is contradictory information regarding the effect of PBM on (pre)malignant cells, which has led to questions regarding the safety of this technique. We address this issue using an orthotopic mouse model (Cal-33) with human squamous cell carcinoma of the oral cavity. METHODS: Mice with actively growing orthotopic Cal-33 head and neck carcinoma tumors were divided into 4 groups: control, PBM only, radiation therapy (RT) only, and PBM + RT. We performed three experiments: (1) PBM at 660 nm, 18.4 J/cm2, and 5 RT × 4 Gy doses delivered daily; (2) PBM at 660 nm, 18.4 J/cm2, and 1 × 15 Gy RT; and (3) PBM at 660 nm + 850 nm, 45 mW/cm2, 3.4 J/cm2, and 1 × 15 Gy RT. Mice were weighed daily and tumor volumes were evaluated by IVIS. Survival time was also evaluated. RESULTS: Animals treated with RT survived significantly longer and had significantly smaller tumor volume when compared with the control and PBM-only treatment groups. No significant differences were noted between the RT alone and PBM + RT groups in any of the experiments. CONCLUSION: Our results suggest that PBM at the utilized parameters does not provide protection to the tumor from the killing effects of RT.
BACKGROUND: Photobiomodulation (PBM) has shown efficacy in preventing and treating cancer therapy-induced mucositis and dermatitis. However, there is contradictory information regarding the effect of PBM on (pre)malignant cells, which has led to questions regarding the safety of this technique. We address this issue using an orthotopic mouse model (Cal-33) with humansquamous cell carcinoma of the oral cavity. METHODS:Mice with actively growing orthotopic Cal-33 head and neck carcinoma tumors were divided into 4 groups: control, PBM only, radiation therapy (RT) only, and PBM + RT. We performed three experiments: (1) PBM at 660 nm, 18.4 J/cm2, and 5 RT × 4 Gy doses delivered daily; (2) PBM at 660 nm, 18.4 J/cm2, and 1 × 15 Gy RT; and (3) PBM at 660 nm + 850 nm, 45 mW/cm2, 3.4 J/cm2, and 1 × 15 Gy RT. Mice were weighed daily and tumor volumes were evaluated by IVIS. Survival time was also evaluated. RESULTS: Animals treated with RT survived significantly longer and had significantly smaller tumor volume when compared with the control and PBM-only treatment groups. No significant differences were noted between the RT alone and PBM + RT groups in any of the experiments. CONCLUSION: Our results suggest that PBM at the utilized parameters does not provide protection to the tumor from the killing effects of RT.
Entities:
Keywords:
Head and neck cancer; Orthotopic mouse model; Photobiomodulation; Radiation therapy
Authors: Águida Cristina Gomes Henriques; Fernanda Ginani; Ruth Medeiros Oliveira; Tatjana Souza Lima Keesen; Carlos Augusto Galvão Barboza; Hugo Alexandre Oliveira Rocha; Jurema Freire Lisboa de Castro; Ricardo Della Coletta; Roseana de Almeida Freitas Journal: Lasers Med Sci Date: 2014-02-14 Impact factor: 3.161
Authors: Felipe F Sperandio; Fernanda S Giudice; Luciana Corrêa; Décio S Pinto; Michael R Hamblin; Suzana C O M de Sousa Journal: J Biophotonics Date: 2013-04-02 Impact factor: 3.207
Authors: Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun Journal: Front Oncol Date: 2022-08-30 Impact factor: 5.738
Authors: René-Jean Bensadoun; Joel B Epstein; Raj G Nair; Andrei Barasch; Judith E Raber-Durlacher; Cesar Migliorati; Marie-Thérèse Genot-Klastersky; Nathaniel Treister; Praveen Arany; Joy Lodewijckx; Jolien Robijns Journal: Cancer Med Date: 2020-10-26 Impact factor: 4.452